If this is your first time in the Forum, please Register 

< class="menu-mobilenav-container">
Questions for Don K...
 
Notifications
Clear all

[Sticky] Questions for Don King - Global FMD situation  

  RSS

Nadia Rumich
Active Member
Joined: 11 months ago
Posts: 7
08/12/2020 10:54 am  
  1. Can you elaborate on the current situation and challenges of getting ‘real-time’ lab data to inform control programmes , and how can this be improved?
  2. You talked about the quality and performance of FMDV vaccines, incl. field testing. However, booster vaccination is still not widely used. Can you give an estimation of the coverage with booster vaccination on global and regional levels, and how this can be improved?
  3. You mentioned difficulties to arrange international shipments. This was also a problem before the COVID-19 situation. What are possible developments to overcome these difficulties, and what is the role other international FMD ref. labs can play?
  4. Some of the risk factors that you mention for trans-pool spread of FMD are also implicated in the spread of other diseases such as LSD and ASF.  Are there unrealised opportunities to better integrate both surveillance and control for these transboundary animal diseases?
This topic was modified 11 months ago by Enrique

Quote
dr khaled
New Member
Joined: 11 months ago
Posts: 1
08/12/2020 11:07 am  

can please tell me where did O3039 come from?

and what is the r1 value for it? 


ReplyQuote
Don King
Active Member
Joined: 11 months ago
Posts: 5
08/12/2020 11:58 am  

Dear Dr Khaled

O-3039 is a vaccine supplied by Boehringer Ingelheim - I suggest that you contact the company for further information about this vaccine strain.

In terms of vaccine matching data (r1-values) - you can find these values in the quarterly reports of WRLFMD/EuFMD (see: https://www.wrlfmd.org/ref-lab-reports)

All the best 

Don 


ReplyQuote
Don King
Active Member
Joined: 11 months ago
Posts: 5
08/12/2020 12:24 pm  

In the discussion forum, I briefly introduced our ideas to develop a dynamic "FMD Dashboard" to allow users to browse, analyse and retrieve FMD datasets.  We are still at the planning stages for these tools and welcome any feedback. The survey (in the link below) has been put together to try to capture and prioritise the requirements for this system - if you are interested, please feel free to complete this survey - or pass on to others that might want to influence how we develop this capacity:

https://forms.office.com/Pages/ResponsePage.aspx?id=Eh70v1zu20izMQzOHucOut-ijsc2qwZOo151ynO2MwhUN01SUFVROTc3TTRYRklEMTU3WU1FTUsyQy4u .

Many thanks

Don 

This post was modified 11 months ago by Enrique

Enrique liked
ReplyQuote
Don King
Active Member
Joined: 11 months ago
Posts: 5
08/12/2020 12:55 pm  

RE: the importance of booster vaccination doses for FMD

I didn't have much time in the talk to cover FMD vaccines - but the question raised here is very important. I am not sure that I can directly answer the question - but there are certainly many anecdotal reports of FMD vaccines being used in the field with only a single dose of the vaccine.  There are a number of published studies that clearly demonstrate the benefits of booster (two shots) to provide broader, higher FMDV-specific immunity with a longer duration - and (as far as I'm aware) most of the vaccination regimes provided by the commercial suppliers require that two doses are given (except where emergency vaccination coverage is required).

Perhaps what confuses this issue, is the fact that vaccine potency assessments (PD50 etc..) are done after only one dose - at ~21 days post vaccination. In my opinion, more studies are required to investigate the impact of booster doses - particularly wrt looking at the antibody titres and the clinical outcomes (protected vs not protected).


ReplyQuote
Share:

Partners

EuFMD Open Session

Special edition

EuFMD Highlights

Contact us

EuFMD Secretariat FAO HQ, Room C-516 Viale delle Terme di Caracalla. 

Rome 00153, Italy

Click to rate this post!
[Total: 0 Average: 0]